Coagulation Testing Market by Product, Test Type, End-User

List of Tables

[192 Pages Report] The Coagulation Testing Market size was estimated at USD 4.62 billion in 2023 and expected to reach USD 5.07 billion in 2024, at a CAGR 9.92% to reach USD 8.96 billion by 2030.

Coagulation testing encompasses a range of diagnostic procedures aimed at assessing the blood's ability to clot properly. These tests are critical in diagnosing and managing various conditions that affect the blood's clotting capability, such as hemophilia, thrombosis, and liver disease. They are also essential in monitoring patients on anticoagulation therapy to ensure safe and effective treatment outcomes. The rising prevalence of cardiovascular diseases and blood disorders has increased the adoption of coagulation testing. Additionally, the aging global population at higher risk of blood-related disorders also significantly raises the need for coagulation testing. However, the high cost of coagulation testing devices and stringent regulatory requirements for the new devices' approval delay product launches, affecting market dynamics. Despite these challenges, increasing investment in healthcare infrastructure in emerging economies provides a future growth prospect. Furthermore, ongoing research and development activities aiming to introduce innovative and efficient coagulation testing solutions are expected to offer new avenues for expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.62 billion
Estimated Year [2024]	USD 5.07 billion
Forecast Year [2030]	USD 8.96 billion
CAGR (%)	9.92%

Product: Rising deployment of automated instruments to achieve efficiency and scalability in coagulation testing

Consumables in coagulation testing include reagents, test strips, and other single-use materials integral to conducting a coagulation test. These are essential for accurately detecting and measuring blood clotting times, factors, and other related parameters. Coagulation testing instruments range from basic manual devices to fully automated systems. These machines are used for various tests such as Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and more. The choice between manual and automated systems is generally based on the volume of tests a laboratory performs and the complexity of the tests required.

End-User: Growing adoption of home coagulation testing kits to support remote patient monitoring

Clinical laboratories represent a significant segment of the coagulation testing market. These facilities require comprehensive and advanced coagulation testing solutions to offer accurate and reliable diagnostic services for a variety of bleeding and clotting disorders. The preference in clinical laboratories leans towards high-throughput coagulation analyzers that can handle a large volume of samples efficiently. The demand for home testing solutions in coagulation testing has surged, driven by the increasing emphasis on patient-centered care and the need for continuous monitoring of patients on anticoagulation therapy. Home testing kits appeal to patients seeking convenience and minimal disruption to daily life. Hospitals require a diverse range of coagulation testing capabilities to cater to the needs of different departments, from emergency rooms to specialized coagulation clinics. The preference in this segment is for versatile and rapid coagulation analyzers that facilitate quick decision-making in acute care settings.

Regional Insights

In the Americas, coagulation testing is getting highly adopted owing to the high prevalence of cardiovascular diseases and an increasing aging population, particularly in North America. The United States showcases higher adoption, supported by advanced healthcare infrastructure and favorable reimbursement policies. The EMEA region presents diverse scenarios in the coagulation testing market, with Europe having a high adoption rate. The growth in Europe is spurred by the increasing adoption of point-of-care (POC) testing devices for faster and more efficient diagnosis, alongside strong healthcare systems and a higher level of patient awareness. The Middle East and Africa are witnessing gradual growth, with initiatives by governments and NGOs to improve healthcare facilities. Asia-Pacific is projected to be the biggest market for coagulation testing, driven by rapidly developing healthcare infrastructure and a large patient pool. Countries inclduing China and India are at the forefront of the adoption of coagulation testing, with their growing middle-class populations and increased focus on healthcare reform. Furthermore, the expanding research and development activities in the region to develop affordable testing solutions are expected to boost the market in this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Coagulation Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Coagulation Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Coagulation Testing Market, highlighting leading vendors and their innovative profiles. These include A&T Corporation, Abbott Laboratories, Advin Health Care, Becton, Dickinson and Company, Beijing Succeeder Technology Inc., Bio Group Medical System SRL, Bio-Rad Laboratories, Inc., Coagulation Sciences LLC, Danaher Corporation, Drucker Diagnostics, LLC, F. Hoffmann-La Roche Ltd, Genrui Biotech Inc., Helena Laboratories Corporation, HORIBA, Ltd., Maccura Biotechnology Co., Ltd., Medtronic PLC, Mindray Bio-Medical Electronics Co., Ltd., Sekisui Chemical Co., Ltd., Shenzhen Micropoint Biotechnologies Co., Ltd., Siemens Healthineers AG, Stago Group, Sysmex Corporation, Thermo Fisher Scientific Inc., Trivitron Healthcare, and Tulip Diagnostics (P) Ltd.

Market Segmentation & Coverage

This research report categorizes the Coagulation Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Consumables
- Instruments

Test Type
- Activated Partial Thromboplastin Time
- Prothrombin Time
- Thrombin Time

End-User
- Clinical Laboratories
- Home Testing
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Coagulation Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Coagulation Testing Market?

3. What are the technology trends and regulatory frameworks in the Coagulation Testing Market?

4. What is the market share of the leading vendors in the Coagulation Testing Market?

5. Which modes and strategic moves are suitable for entering the Coagulation Testing Market?

Product Code: MRR-BF590674206B

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of coagulation disorders worldwide
  - 5.1.1.2. Government campaigns promoting awareness of life-threatening blood clots
- 5.1.2. Restraints
  - 5.1.2.1. Lack of reimbursements for coagulation testing
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in coagulation testing technologies
  - 5.1.3.2. Emergence of coagulation testing for homecare
- 5.1.4. Challenges
  - 5.1.4.1. Technical limitations and inaccuracies of coagulation testing
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising deployment of automated instruments to achieve efficiency and scalability in coagulation testing
- 5.2.2. End-User: Growing adoption of home coagulation testing kits to support remote patient monitoring
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Coagulation Testing Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Instruments

7. Coagulation Testing Market, by Test Type

7.1. Introduction
7.2. Activated Partial Thromboplastin Time
7.3. Prothrombin Time
7.4. Thrombin Time

8. Coagulation Testing Market, by End-User

8.1. Introduction
8.2. Clinical Laboratories
8.3. Home Testing
8.4. Hospitals

9. Americas Coagulation Testing Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Coagulation Testing Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Coagulation Testing Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need
- 12.3.2. HORIBA UK to Introduce New Fully Automated Haemostasis Analysers at IBMS Congress 2023
- 12.3.3. Diagnostica Stago Nabs FDA 510(k) Clearance for Coagulation Analyzers
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio